Switch theme
Sign up to access all valuation multiples
Saudi Pharmaceutical Industries & Medical Appliances Corp is involved in the manufacturing of basic chemical substances and products; medicines for human use, including cosmetics; pharmaceutical production and wholesale and retail of medicines and related products; development and marketing of medicinal and pharmaceutical products; research and development in medical science activities; operating and maintaining the healthcare facilities and any investments in related industries. Its geographical segments are Saudi Arabia, Egypt, the Middle East, Morocco and Algeria.
1986
n/a
LTM Revenue $472M
LTM EBITDA $69.9M
$1.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SPIMACO has a last 12-month revenue of $472M and a last 12-month EBITDA of $69.9M.
In the most recent fiscal year, SPIMACO achieved revenue of $441M and an EBITDA of $46.4M.
SPIMACO expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SPIMACO valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $381M | $441M | XXX | XXX | XXX |
| Gross Profit | $165M | $151M | XXX | XXX | XXX |
| Gross Margin | 43% | 34% | XXX | XXX | XXX |
| EBITDA | -$5.3M | $46.4M | XXX | XXX | XXX |
| EBITDA Margin | -1% | 11% | XXX | XXX | XXX |
| Net Profit | $7.1M | -$44.1M | XXX | XXX | XXX |
| Net Margin | 2% | -10% | XXX | XXX | XXX |
| Net Debt | $251M | $193M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, SPIMACO's stock price is SAR 25 (or $7).
SPIMACO has current market cap of SAR 3.0B (or $793M), and EV of SAR 4.2B (or $1.1B).
See SPIMACO trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.1B | $793M | XXX | XXX | XXX | XXX | $0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, SPIMACO has market cap of $793M and EV of $1.1B.
SPIMACO's trades at 2.4x LTM EV/Revenue multiple, and 16.1x LTM EBITDA.
Analysts estimate SPIMACO's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for SPIMACO and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.1B | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 24.2x | XXX | XXX | XXX |
| P/E | -216.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -60.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSPIMACO's NTM/LTM revenue growth is 9%
SPIMACO's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, SPIMACO's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate SPIMACO's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for SPIMACO and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 11% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -984% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 20% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 39% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SPIMACO acquired XXX companies to date.
Last acquisition by SPIMACO was XXXXXXXX, XXXXX XXXXX XXXXXX . SPIMACO acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was SPIMACO founded? | SPIMACO was founded in 1986. |
| Where is SPIMACO headquartered? | SPIMACO is headquartered in Saudi Arabia. |
| Is SPIMACO publicy listed? | Yes, SPIMACO is a public company listed on SAU. |
| What is the stock symbol of SPIMACO? | SPIMACO trades under 2070 ticker. |
| Who are competitors of SPIMACO? | Similar companies to SPIMACO include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of SPIMACO? | SPIMACO's current market cap is $793M |
| What is the current revenue of SPIMACO? | SPIMACO's last 12-month revenue is $472M. |
| What is the current EBITDA of SPIMACO? | SPIMACO's last 12-month EBITDA is $69.9M. |
| What is the current EV/Revenue multiple of SPIMACO? | Current revenue multiple of SPIMACO is 2.4x. |
| What is the current EV/EBITDA multiple of SPIMACO? | Current EBITDA multiple of SPIMACO is 16.1x. |
| What is the current revenue growth of SPIMACO? | SPIMACO revenue growth between 2023 and 2024 was 16%. |
| Is SPIMACO profitable? | Yes, SPIMACO is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
